Effect of hydrogen inhalation on IL-40 and SIgA in a Rat Model of Pulmonary Mucosal Immunity
Ma Y, Li Z, Zhao Y, Sun M, Sun W, Wang J · 2020
Research-use notice
Independent study record
Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.
H2HUBB TAKEAWAY
In rats, hydrogen inhalation significantly ameliorated lung pathology and airway wall remodeling, increased the protein expression of SIgA, PIgR, IL-4, IL-5, and IL-40, and reduced the protein expression of TGF-β1. These preclinical findings add evidence supporting molecular hydrogen's therapeutic potential within the outcomes and biological pathways measured in this model.
What the Findings Mean
H2HUBB reviewed how inhaled hydrogen gas affected the outcomes measured in rats. Hydrogen inhalation significantly ameliorated lung pathology and airway wall remodeling, increased the protein expression of SIgA, PIgR, IL-4, IL-5, and IL-40, and reduced the protein expression of TGF-β1.
What the Researchers Studied
The researchers studied rats. The study used a preclinical animal experiment. The comparison condition was control condition or baseline measurements.
What Effects Did Molecular Hydrogen Have?
Source-reported hydrogen concentration: 41.6% source-reported H₂ gas concentration; Source-reported hydrogen exposure: 41.6% source-reported H₂ gas concentration; reported treatment duration: 4 months. Hydrogen inhalation significantly ameliorated lung pathology and airway wall remodeling, increased the protein expression of SIgA, PIgR, IL-4, IL-5, and IL-40, and reduced the protein expression of TGF-β1. The authors concluded that inhalation of 22% and 41.6% hydrogen showed a better effect than inhalation of 2% hydrogen. Hydrogen inhalation can significantly improve the expression of SIgA on the mucosal surface of COPD rats, which may be one of the mechanisms which hydrogen works on COPD pathogenesis. The mechanism may be the anti-inflammatory effect of hydrogen, which can reduce the release of inflammatory mediators and decrease the inflammatory factors to improve lung pathological status in COPD rats.
Why These Findings Matter
These preclinical findings add evidence supporting molecular hydrogen's therapeutic potential within the outcomes and biological pathways measured in this model.
How Strong Is This Evidence?
This is preclinical animal evidence from a preclinical animal experiment. It is most informative for the disease model, mechanisms, biomarkers, and outcomes directly measured in the study.
Technical Study Details
H2HUBB classifies this publication as animal study with preclinical animal evidence. The research population or model was rats. The study used a preclinical animal experiment. The hydrogen delivery method was inhaled hydrogen gas. The source-reported hydrogen concentration was 41.6% source-reported H₂ gas concentration. The reported treatment duration was 4 months.
Limitations and Safety
Reported limitations: It is The copyright holder for this preprintthis version posted June 29, 2020.; https://doi.org/10.1101/2020.06.29.177345doi: bioRxiv preprint Introduction Chronic Obstructive Pulmonary Disease (COPD) is a common, preventable and treatable disease, which is characterized by irreversible airflow limitation due to airway and/or alveolar abnormalities, usually caused by significant exposure to harmful particles or gases(1, 2).
Original Study and H2HUBB Research Context
H2HUBB presents this source-grounded research record as one contribution to the broader molecular-hydrogen evidence base. The original scholarly source is available at https://www.biorxiv.org/content/biorxiv/early/2020/06/29/2020.06.29.177345.full.pdf.